Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Common Share

Net Loss per Common Share

6 Months Ended

Jun. 30, 2022

11. Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock, $0.001 par value per share (the “Common Stock”) outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.

The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the six months ended June 30, 2022:



	Six Months Ended June 30,
	2022	2021
Warrants to purchase Common Stock	4,359,193	4,522,654
Options to purchase Common Stock	820,990	828,490
Unvested Restricted Stock	18,710,303	16,389,156
Unvested Restricted Stock Units	121,683	215,684
Total	24,012,169	21,955,984